Release Details
Voyager Therapeutics to Present at the Credit Suisse Healthcare Conference
Credit Suisse Healthcare Conference ,Scottsdale, AZ
Date:Wednesday, November 13, 2019
Presentation Time:10:20 a.m. MST
A live-streaming webcast of the presentation can be accessed through the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days after the live event concludes.
About
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly-owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, a monogenic form of ALS called SOD1, Friedreich’s ataxia, Alzheimer’s disease, and other neurodegenerative diseases related to defective or excess aggregation of tau and alpha-synuclein proteins in the brain. Voyager has strategic collaborations with
Investor Relations:
Chief Financial Officer
857-856-4145
investors@voyagertherapeutics.com
Media:
W2O Group
949-903-4750
sseapy@w2ogroup.com
Source: Voyager Therapeutics, Inc.